Anlon HealthcareNSE:AHCL +0.78%17 PB Ratio is 3.60 as of Jul. 11, 2026, which is 4% above its 10-year median of 3.45. GuruFocus rates NSE:AHCL with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 919 Drug Manufacturers companies, Anlon Healthcare ranks worse than 73.34% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-11), Anlon Healthcare's share price is ₹15.59. Anlon Healthcare's Book Value per Share for the quarter that ended in Mar. 2026 was ₹4.33. Hence, Anlon Healthcare's PB Ratio of today is 3.60.
The historical rank and industry rank for Anlon Healthcare's PB Ratio or its related term are showing as below:
NSE:AHCL'
s PB Ratio Range Over the Past 10 Years
Min: 2.61 Med: 3.45 Max: 8.89
Current: 3.53
During the past 5 years, Anlon Healthcare's highest PB Ratio was 8.89. The lowest was 2.61. And the median was 3.45.
NSE:AHCL's PB Ratio is ranked worse than 73.34% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs NSE:AHCL: 3.53
During the past 12 months, Anlon Healthcare's average Book Value Per Share Growth Rate was 186.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 214.70% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Anlon Healthcare was 273.70% per year. The lowest was 214.70% per year. And the median was 244.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Anlon Healthcare PB Ratio Related Terms
Anlon Healthcare PB Ratio Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's PB Ratio distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Anlon Healthcare (NSE:AHCL) has a PB Ratio of 3.60 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Anlon Healthcare and its competitors. This is near median its historical median of 3.45. Over the past decade, Anlon Healthcare's PB Ratio has ranged from 2.61 to 8.89. According to the industry distribution chart, Anlon Healthcare ranks #674 out of 919 companies in the Drug Manufacturers industry, placing it in the top 73.3%.
Is Anlon Healthcare's PB Ratio too high?
Anlon Healthcare's current PB Ratio of 3.60 is near median its 10-year median of 3.45. Over the past 10 years, this metric has ranged from a low of 2.61 to a high of 8.89. The Drug Manufacturers industry median PB Ratio is 1.90. Anlon Healthcare's value of 3.60 is 89.5% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #674 out of 919 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Anlon Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #674 out of 919 companies for PB Ratio. This places Anlon Healthcare in the lower half of its industry. The industry median PB Ratio is 1.90. Anlon Healthcare's value of 3.60 is 89.5% above this benchmark. Historically, Anlon Healthcare's own PB Ratio has ranged from 2.61 to 8.89 over the past decade. While the company's 10-year median is 3.45 vs. the industry median of 1.90, Anlon Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current PB Ratio of 3.60 is 89.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current PB Ratio is 3.60, which is near median its own 10-year median of 3.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current PB Ratio of 3.60. The current PB Ratio is 3.60, which is near median its 10-year median of 3.45 and 89.5% above the Drug Manufacturers industry median of 1.90. Anlon Healthcare's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current PB Ratio is 3.60 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
17GF Score
Get the complete analysis for NSE:AHCL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
